← Back to Search

Cannabinoid

CBD for Opioid Use Disorder

Phase 2

Recruiting

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be 18 years of age or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0-6 weeks, 6-12 weeks, 0-12 weeks, 0-16 weeks

Awards & highlights

Study Summary

This trial is testing if CBD can help reduce anxiety, pain, and the need for opioids while also improving sleep and cognitive function. It is double-blind, meaning neither the participants nor the researchers will know who is receiving the placebo and who is receiving CBD until the trial is over.

Who is the study for?

Adults with a desire to reduce pain or opioid use through cannabidiol (CBD) can join this study. Excluded are those using recreational drugs, heavy alcohol users, severe opioid addicts unless stable and approved by doctors, people treated for certain mental disorders within the last year, pregnant/nursing women not on birth control, and anyone with unstable medical conditions.Check my eligibility

What is being tested?

The trial is testing two forms of CBD against a placebo to see if they help lower opioid use and relieve anxiety, pain while improving sleep and cognitive function. Participants will be randomly assigned one of these treatments for 12 weeks in a double-blind setup where neither they nor the researchers know who's getting what.See study design

What are the potential side effects?

While specific side effects aren't listed here, CBD may cause fatigue, changes in appetite or weight, diarrhea, and could interact negatively with other medications. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0-6 weeks, 6-12 weeks, 0-12 weeks, 0-16 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0-6 weeks, 6-12 weeks, 0-12 weeks, 0-16 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-6 weeks, 6-12 weeks, 0-12 weeks, 0-16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction in anxiety

Reduction in opioid use

Reduction in pain

+1 more

Secondary outcome measures

Change in Anandamide (AEA)

Change in inflammation

Change in opioid craving

+2 more

Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Broad-spectrum CannabidiolActive Control1 Intervention

210mg/day of broad-spectrum cannabidiol, containing 0%THC.

Group II: Full-spectrum CannabidiolActive Control1 Intervention

210mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.

Group III: Hemp Seed Oil PlaceboPlacebo Group1 Intervention

210mg/day of hemp-seed oil with no cannabinoids present.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor

1,738 Previous Clinical Trials

2,149,376 Total Patients Enrolled

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05299944 — Phase 2

Opioid Use Disorder Research Study Groups: Broad-spectrum Cannabidiol, Full-spectrum Cannabidiol, Hemp Seed Oil Placebo

Opioid Use Disorder Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT05299944 — Phase 2

Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05299944 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Broad-spectrum Cannabidiol attained approval from the Food and Drug Administration?

"There is limited evidence corroborating the safety of Broad-spectrum Cannabidiol, therefore it was given a rating of 2 on our internal scale."

Answered by AI

What is the upper limit for participants in this clinical examination?

"Affirmative. Per the details on clinicaltrials.gov, this venture is in full swing and admitting individuals to participate as of March 17th 2022. The trial was initiated February 1st 2020 and requires a total of 150 participants at one site."

Answered by AI

What objectives is this research endeavor attempting to accomplish?

"This clinical trial will span 12 weeks and its primary outcome is to measure the alteration in pain interference. Secondary outcomes include changes of inflammation, anandamide (AEA), and opioid craving levels over this duration - measured with respective tools such as a likert scale for cravings."

Answered by AI

Is the trial recruiting new participants?

"According to clinicaltrials.gov, the medical research study is presently seeking participants and was initially posted on February 1st 2022 before being revised most recently on March 17th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Reducing Pain and Opioid Use With CBD

2022. "Reducing Pain and Opioid Use With CBD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05299944.

All > Cbd > Epidiolex